Develop and drive the biomarker strategy for clinical stage Epstein Barr Virus (EBV) vaccine programs.

- Oversaw routine analytical testing using cell-based methods and immunoassays across multiple pre-clinical and clinical CAR-T programs to support Process Development, QC, investigations and IND filings - Developed and led a high-performing team of 7 scientists, responsible for goal setting, budget, strategy, vision, and resource/demand planning- Drove the career advancement of two team members from their initial roles as individual contributors to positions of managerial responsibility- Supported phase I lot release testing for B-cell lymphoma directed CAR-T cells- Enhanced departmental communication efficiency and information flow through building and maintaining a strong, cross-functional network- Actively contributed as a key member of the strategic leadership team of the Process and Analytical Development department, shaping the direction and vision of the organization

- Led extended characterization of CAR-T products through CyTOF/Mass Cytometry- Built and managed team to execute CAR-T product analytical testing to support Process Development, Investigations and IND filings across several pre-clinical and clinical CAR-T programs- Supported restructuring of Analytical Development department through harmonizing two separate analytical testing groups

- Led extended characterization of CAR-T products through CyTOF/Mass Cytometry- Built and managed team to execute CAR-T product analytical testing to support Process Development, Investigations and IND filings across several pre-clinical and clinical CAR-T programs

- Built Mass Cytometry routine testing platform that supports deep immunophenotyping (35-40 parameters) of several hundred samples per year (implemented technology, built team, authored documentation)- Supported extended characterization of CAR-T cells and CD34 stem cells from clinical materials (drug product, starting material, peak expansion samples) - Developed a team from ground up providing analytical testing of cell drug products using various cell-based assays (VCN, identity, potency) - Supported cross-functional team to develop and qualify CAR-T identity release assay for IND- Supported correlative studies in a cross-functional team to assess biomarkers of manufacturing and clinical outcome (results reported at scientific conferences such as ASH and ASGCT)

– Assay Development flow cytometry, CyTOF, NextGen sequencing– Analysis of high-dimensional cytometry data – Immunophentyping for clinical cancer immunotherapy studies (phase I and II)– Characterization of Tumor-Microenvironment– Processing and banking of patient samplesScientist II (10/2016 - 9/2017)– Designed and validated Immuno-Oncology Mass Cytometry/CyTOF panels– Organized and chaired DFCI CyTOF Analysis group meetings with 35+ participants– Improved quality control and analysis pipeline for Flow Cytometry assays– Supervised junior scientists with Flow Cytometry experimental design, analysis and troubleshooting– Co-supervised Flow Cytometry, Mass Cytometry/CyTOF and NextGen Sequencing experiments for Phase I and Phase II clinical immunotherapy studies– Co-supervised 5 technicians and one intern

- Characterized PBMCs of HIV-specific CD8+ T-cell responses using Mass Cytometry- Spearheaded CyTOF technology by managing instrument, supporting collaborators and developing new standardization strategies- Mapped HIV, CMV and EBV-specific CD8+ T-cell responses from different cohorts of HIV-infected subjects- Visiting Scientist at Parirenyatwa Hospital, Harare, Zimbabwe: Supported building of state-of the-art immunology research lab to characterize T-cell responses in pediatric HIV patients - Supervised and mentored two technicians and one PhD-level scientist as direct reports